Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13D 0001559834 XXXXXXXX LIVE COMMON STOCK, $0.001 PER SHARE PAR VALUE 04/16/2025 false 0001931055 58500G107 Medinotec Inc. NORTHLANDS DECO PARK, 10 NEW MARKET ST. STAND 299 AVANT GARDE AVENUE JOHANNESBURG T3 2169 Stavros G. Vizirgianakis 27 87 330 2301 C/O XTANT MEDICAL HOLDINGS, INC. 664 CRUISER LANE BELGRADE MT 59714 0001559834 N Stavros G. Vizirgianakis PF N T3 4750179.00 0.00 4750179.00 0.00 4750179.00 N 40.4 IN (Item 13) Based on a total of 11,733,750 shares of the Issuer's common stock outstanding as of January 13, 2025 as stated in the Issuer's Form 10-Q for the quarter ended November 30, 2024 filed with the SEC on January 14, 2025. COMMON STOCK, $0.001 PER SHARE PAR VALUE Medinotec Inc. NORTHLANDS DECO PARK, 10 NEW MARKET ST. STAND 299 AVANT GARDE AVENUE JOHANNESBURG T3 2169 Full address as follows: Northlands Deco Park | 10 New Market Street | Stand 299 Avant Garde Avenue | North Riding | Johannesburg | South Africa 2169. Stavros G. Vizirgianakis C/O XTANT MEDICAL HOLDINGS, INC. 664 CRUISER LANE BELGRADE, MT 59714 The Reporting Person is currently a board member of the Company. The Company is located at Northlands Deco Park, 10 New Market Street, Stand 299 Avant Garde Avenue, North Riding, Johannesburg, South Africa 2169 No No Monaco The Reporting Person holds 4,750,179 shares of common stock, which were acquired on April 26, 2021 in connection with the issuance of 10,000,000 shares of common stock to the founding shareholders at 0.001 per share. The purpose of this Schedule 13D is to report the Beneficial Ownership by the Reporting Person of 4,750,179 shares of common stock or 40.4% of the Issuer's issued and outstanding common stock as of January 13, 2025. The Reporting Person has no present plans or proposals which relate to or would result in any of the actions specified in clauses (a) through (j) of Item 4. The Reporting Person may, from time to time, determine to acquire additional Common Stock, to dispose of some or all of his Common Stock, discuss the Issuer's business, operations or other affairs with the Issuer's management, board of directors, shareholders, or others or take such other action as he deems appropriate. The Reporting Person reserves the right to change his intentions and adopt plans or proposals in the future that could result in any of the transactions specified in clauses (a) through (j) of Item 4, or any other transaction which the Reporting Person believes could enhance shareholder value. The Reporting Person is currently the beneficial owner of 4,750,179 shares of common stock of the Issuer, representing approximately 40.4% of the Issuer's common stock (based upon 11,733,750 outstanding shares of common stock as of January 13, 2025 as reported in the Company's Quarterly Report on Form 10-Q filed with the SEC on January 14, 2025). The Reporting Person has sole voting and dispositive power over the Shares identified in response to Item 5(a) above. Aside from the following, the Reporting Person has not effected any transactions in shares of common stock in the past 60 days. Not applicable. Not applicable. Other than as described in this Schedule 13D, the Reporting Person has no contracts, arrangements, understandings or relationships with any other person with respect to any securities of the Issuer. None Stavros G. Vizirgianakis Stavros G. Vizirgianakis Stavros G. Vizirgianakis / Director 06/12/2025